WO2025099636 - ALBUMIN CONJUGATES AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF
National phase entry is expected:
Publication Number
WO/2025/099636
Publication Date
15.05.2025
International Application No.
PCT/IB2024/061049
International Filing Date
07.11.2024
Title **
[English]
ALBUMIN CONJUGATES AND RADIOPHARMACEUTICAL COMPOSITIONS THEREOF
[French]
CONJUGUÉS D'ALBUMINE ET COMPOSITIONS RADIOPHARMACEUTIQUES ASSOCIÉES
Applicants **
JUBILANT DRAXIMAGE INC
Inventors
NANDI, Indranil
KULANGARA, Vijayaraj Kuniyil
SARWAL, Dinesh Kumar
BHATTACHARYYA, Arundhati
PENA, Miriam Ruiz
ABREU DIAZ, Aida Mary
Priority Data
63/597,218
08.11.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2465 | |
| EPO | Filing, Examination, Granting | 15792 | |
| Japan | Filing, Examination, Granting | 2378 | |
| South Korea | Filing, Examination, Granting | 2580 | |
| USA | Filing, Examination, Granting | 6340 |
Total:
29,555
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The embodiments of the present invention disclose a conjugate compound of formula X-J- MAA, wherein X is a diagnostic or therapeutic radioisotope; J is an optional chelating agent; and MAA is macroaggregated albumin particles. The invention also discloses sterile and stable ready to use or reconstituted radiopharmaceutical composition of X-J-MAA and manufacturing process thereof. The prepared radiopharmaceutical compositions exhibit desirable technical attributes like stability, radiochemical purity, less impurities, pH, better bio-distribution and desirable average particle size for further administration to patients for therapeutic and diagnostic use[French]
Les modes de réalisation de la présente invention concernent un composé conjugué représenté par la formule X-J-MAA, dans laquelle X est un radio-isotope diagnostique ou thérapeutique ; J est un agent chélatant facultatif ; et MAA désigne des particules d'albumine macroagrégées. L'invention concerne également une composition radiopharmaceutique stérile et stable, prête à l'emploi ou reconstituée, de X-J-MAA et son procédé de fabrication. Les compositions radiopharmaceutiques préparées présentent des attributs techniques souhaitables tels qu'en termes de stabilité, pureté radiochimique, teneur inférieure en impuretés, pH, meilleure biodistribution et taille de particules moyenne souhaitable à des fins d'administration ultérieure à des patients pour usages thérapeutique et diagnostique.